Tenaya Therapeutics Inc Net Assets
Tenaya Therapeutics Inc net assets. Based on the latest financial reports, Tenaya Therapeutics Inc (TNYA) has net assets worth $82.87 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($104.98 Million) and total liabilities ($22.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Tenaya Therapeutics Inc to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $82.87 Million |
| % of Total Assets | 78.94% |
| Annual Growth Rate | N/A |
| 5-Year Change | -33.41% |
| 10-Year Change | N/A |
| Growth Volatility | 57.05 |
Net Assets of Tenaya Therapeutics Inc (2019–2024)
Net assets of Tenaya Therapeutics Inc from 2019 to 2024. This chart illustrates how Tenaya Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See Tenaya Therapeutics Inc (TNYA) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Tenaya Therapeutics Inc (2019–2024)
The table below shows the annual net assets of Tenaya Therapeutics Inc from 2019 to 2024. For live market cap and overall valuation, see market cap of Tenaya Therapeutics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $92.85 Million | -33.40% |
| 2023-12-31 | $139.42 Million | -42.71% |
| 2022-12-31 | $243.38 Million | -12.62% |
| 2021-12-31 | $278.53 Million | +99.75% |
| 2020-12-31 | $139.44 Million | +418.80% |
| 2019-12-31 | $-43.74 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tenaya Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46999400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Tenaya Therapeutics Inc Net Assets Breakdown (December 2024)
Tenaya Therapeutics Inc net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.00K | 0.01% |
| Other Comprehensive Income | $28.00K | 0.03% |
| Other Components | $607.23 Million | 653.96% |
| Total Equity | $92.85 Million | 100.00% |
Tenaya Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Tenaya Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JLK Inc
KQ:322510
|
$78.02 Million |
|
Jasa Armada Indonesia Tbk PT
JK:IPCM
|
$78.04 Million |
|
Jetway Information Co Ltd
TWO:6161
|
$78.05 Million |
|
Qua Granite Hayal Yapi ve Urunleri Sanayi Ticaret AS
IS:QUAGR
|
$78.05 Million |
|
Morn Sun Feed Mill Corp
TWO:1240
|
$77.99 Million |
|
Tacheng Real Estate Co Ltd
TWO:6171
|
$77.98 Million |
|
Kuyas Yatirim AS
IS:KUYAS
|
$77.94 Million |
|
Muhibbah Engineering M Bhd
KLSE:5703
|
$77.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tenaya Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 139,424,000 to 92,854,000, a change of -46,570,000 (-33.4%).
- Net loss of 111,129,000 reduced equity.
- New share issuances of 46,762,000 increased equity.
- Other comprehensive income increased equity by 134,000.
- Other factors increased equity by 17,663,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-111.13 Million | -119.68% |
| Share Issuances | $46.76 Million | +50.36% |
| Other Comprehensive Income | $134.00K | +0.14% |
| Other Changes | $17.66 Million | +19.02% |
| Total Change | $- | -33.40% |
Book Value vs Market Value Analysis
This analysis compares Tenaya Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.33x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-1.61 | $0.36 | x |
| 2020-12-31 | $3.39 | $0.36 | x |
| 2021-12-31 | $6.75 | $0.36 | x |
| 2022-12-31 | $5.43 | $0.36 | x |
| 2023-12-31 | $1.89 | $0.36 | x |
| 2024-12-31 | $1.09 | $0.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tenaya Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -119.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.29x
- Recent ROE (-119.68%) is below the historical average (-52.01%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-21.40 Million |
| 2020 | -27.54% | 0.00% | 0.00x | 1.06x | $-52.34 Million |
| 2021 | -25.01% | 0.00% | 0.00x | 1.14x | $-97.50 Million |
| 2022 | -50.81% | 0.00% | 0.00x | 1.15x | $-148.00 Million |
| 2023 | -89.00% | 0.00% | 0.00x | 1.22x | $-138.03 Million |
| 2024 | -119.68% | 0.00% | 0.00x | 1.29x | $-120.41 Million |
Industry Comparison
This section compares Tenaya Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tenaya Therapeutics Inc (TNYA) | $82.87 Million | 0.00% | 0.27x | $78.01 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Tenaya Therapeutics Inc
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ve… Read more